Drug Trial Radar · NCT00648596
A Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion
Last checked: Nov 19, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
780
Actual
Start
May 2003
Primary completion
Not stated
Study completion May 2004
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the improvement in the self-esteem domain score of the Self-Esteem/Overall Relationship (SEAR) questionnaire and the improvement in erectile function (obtained from the Erectile Function \[EF\] domain of the International Index of Erectile Function \[IIEF\]). Furthermore, to determine if the improvement obtained in self-esteem was related to the main erectile dysfunction (ED) co-morbidities type and/or number.
Conditions
- Erectile Dysfunction
Interventions
sildenafilDrug
sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
placeboDrug
placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Self-esteem domain of the SEAR questionnaireTime frame: Week 12
Locations
66 sites in 8 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Oulu, Finland
Pfizer Investigational Site
Tampere, Finland
Pfizer Investigational Site
Turku, Finland
Pfizer Investigational Site
Clermont-Ferrand, France
Pfizer Investigational Site
LE Kremlin Bicentre, France
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Neuilly-sur-Seine, France
Pfizer Investigational Site
Nice, France
Pfizer Investigational Site
Nîmes, France
Pfizer Investigational Site
Toulouse, France
Pfizer Investigational Site
Bari, Italy
Pfizer Investigational Site
Catania, Italy
Pfizer Investigational Site
Gallarate (VA), Italy
Pfizer Investigational Site
Modena, Italy
Pfizer Investigational Site
Padova, Italy
Pfizer Investigational Site
Roma, Italy
Pfizer Investigational Site
Siena, Italy
Pfizer Investigational Site
Torino, Italy
Pfizer Investigational Site
Krakow, Poland
Pfizer Investigational Site
Lodz, Poland
Pfizer Investigational Site
Lublin, Poland
Pfizer Investigational Site
Olsztyn, Poland
Pfizer Investigational Site
Szczecin, Poland
Pfizer Investigational Site
Warsaw, Poland
Pfizer Investigational Site
Barnaul, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Nizhny Novgorod, Russia
Pfizer Investigational Site
Novosibirsk, Russia
Pfizer Investigational Site
Novosibirsk, Russia
Pfizer Investigational Site
Rostov-on-Don, Russia
Pfizer Investigational Site
Saint Petersburg, Russia
Pfizer Investigational Site
Saint Petersburg, Russia
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.